$Altimmune (ALT.US)$ Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include: - Up to 68.5% relative reduction in liver fat con...
DazzyJazzy : 等着大放异彩---
Mad Money Trader : 短裤很快就会烧烤了![调皮 [调皮]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)